SOPH Earnings

SOPH reported its FY2025Q3 earnings on 2025-11-04, showcasing a revenue of 19.00M against an estimate of 18.00M, resulting in a 7.36% surprise. The EPS was -0.3, surpassing the expected 0 by 0% . The stock experienced a -6.4% price change on the earnings day and a -12.6% change over the next five days, reflecting market reactions to the results.

Following SOPH's FY2025Q3 earnings announcement on 2025-11-04, the stock price moved by -6.40% on the day of the release. Over the subsequent five days, it saw a -12.60% change. Historically, SOPH's stock price tends to shift by an average of +2.64% in the 10 days leading up to earnings and -8.76% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate SOPH’s annual revenue to reach 20.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 0.44% and EPS estimates Revise Downward by -1.1% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between SOPH's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 0.44%, while EPS estimates moved Revise Downward by -1.1% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, SOPH's stock price typically moves by +2.64% in the 10 days before its earnings and -8.76% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 20.00M.

The earnings call presents a positive outlook with strong financial metrics, including a 13% YoY improvement in adjusted EBITDA and stable customer retention. The AstraZeneca partnership and growth in clinical and biopharma segments are promising, despite conservative guidance. The Q&A reveals strong momentum and optimism for 2026, with significant potential from MSK-ACCESS and biopharma segments. While some details remain confidential, overall sentiment is positive, suggesting a potential stock price increase of 2% to 8% over the next two weeks.